[ad_1]
The average one-year price target for Apyx Medical (FRA:BOV) has been revised to 7.20 / share. This is an decrease of 5.06% from the prior estimate of 7.58 dated April 6, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 2.76 to a high of 12.43 / share. The average price target represents an increase of 172.59% from the latest reported closing price of 2.64 / share.
See our leaderboard of companies with the largest price target upside.
What is the Fund Sentiment?
There are 93 funds or institutions reporting positions in Apyx Medical. This is a decrease of 14 owner(s) or 13.08% in the last quarter. Average portfolio weight of all funds dedicated to BOV is 0.22%, a decrease of 31.16%. Total shares owned by institutions decreased in the last three months by 8.49% to 20,908K shares.
What are Other Shareholders Doing?
Archon Capital Management holds 3,452K shares representing 9.98% ownership of the company. In it’s prior filing, the firm reported owning 2,694K shares, representing an increase of 21.95%. The firm increased its portfolio allocation in BOV by 9.12% over the last quarter.
Rtw Investments holds 3,398K shares representing 9.82% ownership of the company. No change in the last quarter.
Cowen And Company holds 1,776K shares representing 5.13% ownership of the company. In it’s prior filing, the firm reported owning 2,855K shares, representing a decrease of 60.76%. The firm decreased its portfolio allocation in BOV by 66.13% over the last quarter.
Invenire Partners holds 946K shares representing 2.73% ownership of the company. In it’s prior filing, the firm reported owning 578K shares, representing an increase of 38.89%. The firm increased its portfolio allocation in BOV by 44.37% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 945K shares representing 2.73% ownership of the company. No change in the last quarter.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
